Carcinoma, Intraductal, Noninfiltrating clinical trials at UCSF

1 research study open to eligible people

Intraductal, noninfiltrating carcinoma is breast cancer that doesn't spread beyond milk ducts. UCSF is researching how immunotherapy affects the immune response in high-risk cases. The study examines changes in the immune environment.

Showing trials for

  • Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)

    open to eligible females ages 18 years and up

    This is a study to investigate the change in the immune microenvironment of high risk ductal carcinoma in situ (DCIS) after short term exposure to immunotherapy.

    San Francisco, California

Our lead scientists for Carcinoma, Intraductal, Noninfiltrating research studies include .

Last updated: